Literature DB >> 1886640

Overview: cryptococcosis in the patient with AIDS.

A M Sugar1.   

Abstract

Cryptococcosis is currently the most common life threatening mycoses found in patients with the acquired immunodeficiency syndrome (AIDS). Extrapulmonary involvement is most frequently seen, especially in the central nervous system and skin. Clinical findings are non-specific, even in patients with meningitis. Threshold for diagnosis of this infection should be low, with serum cryptococcal antigens, blood, urine and sputum cultures for Cryptococcus neoformans performed in febrile AIDS patients. Lumbar puncture should also be performed if unexplained headaches are included in a patient's complaints. There is currently no consensus for the most appropriate treatment strategy and the role of oral azoles versus amphotericin B or amphotericin B with flucytosine remains a serious question in need of further controlled studies. Patients eligible for multicentered trials should be encouraged to participate. Therapy for others should be individualized. This review will address some of these issues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1886640     DOI: 10.1007/bf00437205

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  18 in total

1.  Isolation of Cryptococcus neoformans gattii from a patient with AIDS in southern California.

Authors:  M N Clancy; J Fleischmann; D H Howard; K J Kwon-Chung; R Y Shimizu
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

Review 2.  Fluconazole, a new antifungal agent.

Authors:  J N Galgiani
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

3.  Natural habitat of Cryptococcus neoformans var. gattii.

Authors:  D H Ellis; T J Pfeiffer
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

4.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.

Authors:  R A Larsen; M A Leal; L S Chan
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

5.  Poorly encapsulated Cryptococcus neoformans from patients with AIDS. I: Preliminary observations.

Authors:  E J Bottone; M Toma; B E Johansson; G P Wormser
Journal:  AIDS Res       Date:  1986

6.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

Authors:  A M Sugar; C Saunders
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

7.  Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients.

Authors:  J J Stern; B J Hartman; P Sharkey; V Rowland; K E Squires; H W Murray; J R Graybill
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

8.  Itraconazole therapy for cryptococcal meningitis and cryptococcosis.

Authors:  D W Denning; R M Tucker; L H Hanson; J R Hamilton; D A Stevens
Journal:  Arch Intern Med       Date:  1989-10

9.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

10.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

View more
  12 in total

1.  Isolation of opportunistic fungi from bronchoalveolar lavage of compromised hosts in Isfahan, Iran.

Authors:  S Shadzi; M Chadeganipour
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

2.  A vitamin-free minimal synthetic medium for Cryptococcus neoformans.

Authors:  V Vidotto; S Aoki; G Campanini
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

3.  Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins.

Authors:  Marybeth A Maligie; Claude P Selitrennikoff
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group.

Authors:  M E Brandt; L C Hutwagner; L A Klug; W S Baughman; D Rimland; E A Graviss; R J Hamill; C Thomas; P G Pappas; A L Reingold; R W Pinner
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

5.  Ocular complications of HIV infection in sub-Sahara Africa.

Authors:  Oathokwa Nkomazana; Dintle Tshitswana
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

6.  The isolation of Cryptococcus neoformans from pigeon droppings and serotyping of naturally and clinically sourced isolates in China.

Authors:  A Li; K Nishimura; H Taguchi; R Tanaka; S Wu; M Miyaji
Journal:  Mycopathologia       Date:  1993-10       Impact factor: 2.574

7.  Multilocus enzyme typing of Cryptococcus neoformans.

Authors:  M E Brandt; S L Bragg; R W Pinner
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

8.  Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice.

Authors:  S M Muth; J W Murphy
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  Comparison of multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for molecular subtyping of Cryptococcus neoformans. The Cryplococcal Disease Active Surveillance Group.

Authors:  M E Brandt; L C Hutwagner; R J Kuykendall; R W Pinner
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

10.  Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion.

Authors:  Z M Dong; J W Murphy
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.